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a  b  s  t  r  a  c  t
Background:  The  synergistic  effect  of  diabetes  mellitus  (DM)  and  hypertension  on  mid-term  outcome
among  acute  myocardial  infarction  (MI)  patients  undergoing  percutaneous  coronary  intervention  (PCI)
is still  controversial.
Methods:  A  total  of  2438  patients  with acute  MI  who  underwent  PCI  from  January  2007  to November  2010
were studied.  Patients  were  stratiﬁed  to four  groups  according  to the  presence  of DM  or  hypertension
and  followed  up  during  12  months.  We  analyzed  the  inﬂuence  of  hypertension  and DM  on  major  adverse
cardiac  events  (MACE:  death,  recurrent  MI,  repeated  coronary  artery  revascularization).
Results: No  history  of hypertension  or DM  was  found  in  35.0%,  a history  of  hypertension  in  27.2%,  a  history
of  DM  in  15.0%,  and  a history  of  both  disease  entities  in 22.8%.  The  rate  of MACE  was  signiﬁcantly  higher  in
hypertensive  DM  group  (15.9%  vs. 22.9%  vs.  28.8%  vs.  37.0%,  log-rank  p  < 0.001).  In  multivariate  analysis,
hypertension  and  DM  were  meaningful  predictors  of mid-term  mortality,  and  the  combination  of the
two was  a stronger  predictor  (hazard  ratio =  1.790;  95%  conﬁdence  interval  =  1.313–2.442;  p < 0.001).
Conclusions:  After PCI, acute  MI  patients  with  a history  of DM  or hypertension  had a  higher mid-term  mor-
nts  w
iated
2  Japtality than  acute  MI patie
to  be more  strongly  assoc
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Diabetes mellitus (DM) and hypertension are among the most
ommon diseases in the modern world [1].  Hypertension is a
ell-known risk factor for coronary artery disease (CAD), and
here is considerable evidence that the prevalence of hyperten-
ion is approximately twice as high in diabetic patients as in the
on-diabetic population [2–4]. Also, DM continues to be asso-
iated with considerably increased long-term mortality after an
cute myocardial infarction (MI) [5],  and in-hospital mortality
s higher in diabetics [6]. Moreover, each pathophysiologic dis-
ase entity serves to exacerbate the other [7].  Previous studies in
he thrombolytic era concur that DM is an independent risk fac-
or for mortality post-MI [8],  and other studies have shown that
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hypertension is also associated with a worse prognosis post-MI
[9,10].  Despite this consensus, little is known about the combined
impact of hypertension and DM on the outcome after acute MI,
especially in the era of percutaneous coronary intervention (PCI),
although it has been described in the broad spectrum of patients
with acute coronary syndromes (ACS) [11].
Therefore, the aim of the present study was  to assess the mid-
term clinical outcomes among acute MI  patients who  underwent
PCI in relation to a history of hypertension or DM alone or a com-
bination of the two.
Methods
Study population
We  studied 2438 consecutive patients with acute MI  who under-
went PCI in Chonnam National University Hospital (Gwangju,
Republic of Korea) from January 2007 to November 2010. The
present study was designed to analyze the impact of history of
hypertension or DM alone or a combination of the two  on mid-term
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linical outcomes in acute MI  patients who underwent PCI. These
atients were stratiﬁed into four groups, based on their history of
M and hypertension at admission:
Group 1: neither previous diagnosis of DM nor hypertension.
Group 2: previous diagnosis of hypertension and no diabetes.
Group 3: previous diagnosis of diabetes and no hypertension.
Group 4: known diabetes and hypertension.
The eligible patients were ≥18 years old at admission; MI  was
eﬁned as the association of ≥1 clinical and ≥1 biological criteria:
cute-onset chest pain and/or typical modiﬁcation on the 12-lead
lectrocardiogram (ST-segment or T-wave modiﬁcation or new left
undle branch block) and an increase of troponin value >99th per-
entile of the upper reference limit [12]. Patients were excluded if
hey had any general contraindication to the revascularization pro-
edure and pharmacologic therapies, or showed an estimated life
xpectancy <12 months. Routine laboratory measurements includ-
ng cardiac enzymes were done on blood samples drawn as soon as
ossible after admission, and fasting lipid proﬁles were obtained
ithin 24 h of admission. The diagnosis of DM and hypertension
as made on the basis of the reported history and medical records.
he diagnosis of DM is based on one of four abnormalities: (1) glyco-
ylated hemoglobin ≥6.5%; (2) fasting plasma glucose ≥126 mg/dl;
3) classic symptoms of hyperglycemia or hyperglycemic crisis with
andom plasma glucose ≥200 mg/dl; or (4) abnormal oral glucose
olerance test: 2 h postprandial plasma glucose ≥200 mg/dl [13].
ypertension was deﬁned by chronic use of antihypertensive drugs
r a previously documented blood pressure ≥140/90 mmHg  at sta-
le condition.
tudy design
All patients received ≥100 mg  of aspirin and a 300–600 mg  load-
ng dose of clopidogrel and unfractionated heparin (50–70 U/kg)
o maintain an activated clotting time at >250–300 s before,
r at the procedure. Loading doses of aspirin and clopid-
grel were administered after patients agreed to undergo
CI. The maintenance dose was 100 mg/day for aspirin and
5 mg/day for clopidogrel. All patients were prescribed aspirin
nd clopidogrel for 3–12 months depending on stent type. The
ost-intervention medication included aspirin, clopidogrel, beta-
lockers, angiotensin-converting enzyme inhibitors, angiotensin II
eceptor blockers, and statins. After discharge, the patients con-
inued receiving the same medications that they received during
ospitalization except some intravenous or temporary medica-
ions. PCI was performed using the standard techniques if the
oronary anatomy was suitable for angioplasty. The decision for
redilation, direct stenting, postadjunctive balloon inﬂation, and
he administration of glycoprotein IIb/IIIa inhibitors was left to
he discretion of individual operators. Multivessel coronary artery
isease was deﬁned as >50% diameter stenosis by quantitative
oronary angiography in ≥2 coronary arteries or a left main coro-
ary artery lesion. Coronary artery lesion type was  determined
ccording to American College of Cardiology and American Heart
ssociation classiﬁcation. Successful PCI was deﬁned as residual
tenosis <20% in diameter with ﬁnal Thrombolysis In Myocardial
nfarction (TIMI) grade III ﬂow. Left ventricular ejection fraction
LVEF) was determined by echocardiography during the admission
eriod. Clinical follow-up was performed at 1, 6, and 12 months
nd when angina-like symptoms occurred.
We  analyzed baseline demographic and clinical character-
stics, relevant laboratory results, and treatment strategies.
idney function was assessed using estimated glomerular
ltration rate (eGFR) calculated using the 4-variable abbre-
iated MDRD (modiﬁcation of diet in renal disease) studyology 60 (2012) 257–263
equation (eGFR (ml/min/1.73 m2) = 186 × (serum creatinine in
mg/dl)−1.154 × (age)−0.203 × 0.742 (if female) × 1.212 (if black))
[14]. The primary end point was  the composite of major adverse
cardiac events (MACE) during the 12 months of clinical follow-up.
MACE was  deﬁned as the composite of cardiac death, non-cardiac
death, non-fatal recurrent MI,  and repeated coronary artery
revascularization. Non-fatal recurrent MI  was deﬁned as recurrent
symptoms with new electrocardiographic changes compatible
with MI  or cardiac markers at least twice the upper limit of normal.
Repeated coronary artery revascularization included target lesion
revascularization (TLR), target vessel revascularization (TVR), and
non-TVR. TLR was  deﬁned as any revascularization of the target
lesion due to restenosis or reocclusion within 5 mm proximal or
distal to the stent. TVR was  deﬁned as any repeated intervention
driven by the lesions located in the treated vessel within and
beyond the target limits. The secondary end point included indi-
vidual components of the primary end point including cardiac
death, all-cause death, recurrent MI,  coronary revascularization,
and stent thrombosis. Stent thrombosis was  deﬁned as deﬁnite and
probable stent thrombosis according to the Academic Research
Consortium deﬁnition [15].
Statistical analysis
The Statistical Package for Social Science (SPSS) for Windows,
version 17.0 (Chicago, IL, USA) was  used for all analysis. All
continuous variables are expressed as mean ± standard deviation
and evaluated by an analysis of variance. Discrete variables are
expressed as counts and percentages, and were analyzed with a chi-
square test for independence and trend. Event-free survival curves
for the cumulative mortality, death and recurrent MI,  coronary
revascularization, and composite MACE were constructed using the
Kaplan–Meier method and differences between the groups were
assessed by Log-rank test. Cox proportional hazard regression anal-
ysis was  performed to identify independent predictors of 12-month
mortality. All continuous variables were converted into categorical
variables. After considering variate analysis results and collinea-
rity among variables, signiﬁcant variables were entered into a Cox
proportional hazards model in phases. These variables included
gender, age, ST-segment elevation MI  (STEMI), previous history of
cerebrovascular accident (CVA), smoking, Killip class, LVEF, eGFR,
multivessel CAD, implantation of bare-metal stent, postprocedural
TIMI ﬂow grade, use of beta blocker, and use of statin. The enter
method was used to select the predictive variables. Statistical sig-
niﬁcance was  assumed at a p-value < 0.05.
Results
Baseline clinical characteristics
The reference group 1 made up 35.0% of the overall population.
Patients who were not previously known to have DM,  but who
had hypertension upon admission made up 27.2% of the total. Nor-
motensive diabetic patients upon presentation represented 15.0%,
whereas diabetic patients with hypertension contributed to the
remaining 22.8%. Among the total population, 1211 (49.7%) were
STEMI and 1227 (50.3%) were non-STEMI.
Patient characteristics stratiﬁed by the four study subgroups are
shown in Table 1. The oldest group of patients showed known his-
tory of DM and hypertension. Male gender and history of smoking
were more common in the groups with no history of DM and hyper-
tension. Previous history of MI,  previous history of coronary artery
bypass grafting, prior history of CVA, and low eGFR are predominant
in DM patients with hypertension. High Killip class was also most
common among this population, and LVEF was lowest.Laboratory
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Table  1
Baseline clinical characteristics.
Group 1 (n = 854) Group 2 (n = 663) Group 3 (n = 366) Group 4 (n = 555) p-value§
Age (years)† 60.2 ± 13.6a 66.6 ± 12.1b 63.0 ± 12.3c 68.9 ± 10.5d <0.001*
Male gender, n (%) 686 (80.3) 425 (64.1) 282 (77.0) 307 (55.3) <0.001*
Medical history, n (%)
Dyslipidemia 37 (4.3) 40 (6.0) 13 (3.6) 32 (5.8) 0.477
Smoking 609 (71.3) 334 (50.4) 240 (65.6) 232 (41.8) <0.001
Previous history of MI 44 (5.2) 39 (5.9) 14 (3.8) 51 (9.2) 0.012
Previous history of PCI 33 (3.9) 39 (5.9) 14 (3.8) 37 (6.7) 0.060
Previous history of CABG 1 (0.1) 3 (0.5) 4 (1.1) 7 (1.3) 0.003
Prior  CVA 25(2.9) 63 (9.5) 16 (4.4) 70 (12.6) <0.001
Prior  PVD 5 (0.6) 10 (1.5) 3 (0.8) 10 (1.8) 0.075
Prior  heart failure 1 (0.1) 3 (0.5) 1 (0.3) 4 (0.7) 0.101
STEMI, n (%) 449 (52.6) 292 (44.0) 212 (57.9) 258 (46.5) 0.296
Killip  class (III, n (%) 89 (10.4) 72 (10.9) 90 (24.6) 173 (31.2) <0.001
LVEF  (%)† 56.2 ± 11.4a 56.6 ± 11.8a 52.8 ± 13.5b 52.5 ± 13.5b <0.001*
Laboratory ﬁndings
Glucose† 129.2 ± 26.9a 130.9 ± 26.9a 255.2 ± 98.3b 243.6 ± 103.7b <0.001*
HbA1c† 5.9 ± 0.5a 6.0 ± 0.9a 7.7 ± 1.8b 7.5 ± 1.6c <0.001*
eGFR (ml/min)† 89.5 ± 33.9a 72.8 ± 32.3b 80.4 ± 37.0c 61.6 ± 35.5d <0.001*
Total cholesterol (mg/dl)† 187.4 ± 43.6a 181.1 ± 39.5b 180.5 ± 43.8a,b 177.0 ± 49.0b <0.001*
LDL cholesterol (mg/dl)† 120.9 ± 38.8a 115.6 ± 35.8b 113.6 ± 36.5b 111.9 ± 41.3b <0.001*
HDL cholesterol (mg/dl)† 43.2 ± 11.2a 43.4 ± 11.1a 41.7 ± 11.2b 40.5 ± 11.6b <0.001*
Triglyceride (mg/dl)† 126.5 ± 79.6a 115.8 ± 68.6b 135.3 ± 91.0a 131.4 ± 76.4a <0.001*
Peak CK-MB (ng/ml) 69.0 ± 95.1 69.4 ± 100.5 88.9 ± 144.2 74.8 ± 243.2 0.162*
Peak troponin-I (ng/ml) 43.7 ± 68.5 40.2 ± 70.0 53.1 ± 76.7 46.4 ± 113.6 0.104*
hs-CRP (mg/dl)† 1.4 ± 2.9a 2.2 ± 9.0a,b 2.3 ± 4.0b 2.6 ± 4.9b 0.005*
NT Pro-BNP (pg/ml)† 1481.1 ± 3225.1a 3543.6 ± 6972.3b 3107.9 ± 6371.0b 6082.5 ± 9469.2c <0.001*
Medication, n (%)
Aspirin 828 (97.0) 647 (97.6) 352 (96.2) 539 (97.1) 0.867
Clopidogrel 781 (91.5) 624 (94.1) 336 (91.8) 525 (94.6) 0.067
Cilostazol 217 (25.4) 176 (26.5) 82 (22.4) 150 (27.0) 0.825
ACE  inhibitors 342 (40.1) 267 (40.3) 146 (39.8) 201 (36.2) 0.201
ARB 377 (44.1) 325 (49.0) 166 (45.4) 270 (48.6) 0.176
Beta-blockers 682 (79.9) 559 (84.3) 286 (78.1) 457 (82.3) 0.596
Statins 705 (82.6) 542 (81.7) 302 (82.5) 442 (79.7) 0.267
Data are given as mean ± SD or n (%).
Group 1 = neither previous diagnosis of diabetes nor hypertension. Group 2 = previous diagnosis of hypertension and no diabetes. Group 3 = previous diagnosis of diabetes
and  no hypertension. Group 4 = known diabetes and hypertension.
MI,  myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; PVD, peripheral vascular disease;
STEMI,  ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; HbA1c, glycosylated hemoglobin; eGFR, estimated glomerular ﬁltration rate;
LDL,  low-density lipoprotein; HDL, high-density lipoprotein; CK-MB, creatine kinase myocardial band isoenzyme; hs-CRP, high-sensitivity C-reactive protein; NT Pro-BNP,





















p§ Statistical signiﬁcances for linear-by-linear association between categorical var
* Statistical signiﬁcances were tested by analysis of variance among groups.
† The same letters indicate non-signiﬁcant difference between groups based on m
ndings had a varied distribution across groups. Among the four
roups, no signiﬁcant differences were present in the sort of med-
cations that can affect the prognosis of MI  patients.
ngiographic and procedural ﬁndings
Coronary angiographic ﬁndings and procedural characteristics
re summarized in Table 2. Left anterior descending artery as a
ulprit lesion was less frequently observed in the group with a his-
ory of DM and hypertension, but this group showed more frequent
nvolvement of left circumﬂex artery. Multivessel disease was most
ommon in patients to have DM and hypertension. Preprocedural
nd postprocedural TIMI ﬂow grade were not different among the
our groups. Bare-metal stents were most commonly deployed in
ypertensive DM patients and biolimus-eluting stents were most
ommonly deployed in non-diabetic hypertensive patients, but no
igniﬁcant differences across groups were present in the choice
f other drug-eluting stents. A smaller diameter of stents was
eployed in the group with hypertension and DM,  but a fewer
umber of stents was deployed in the “normal” group.linical outcomes
Outcomes of in-hospital period and for each component of the
rimary end points at follow-up period of 6 months and 12 months were tested using chi-square test for trend.
le comparison test.
are summarized in Table 3. In-hospital death was most common
in hypertensive DM patients, and coronary care unit admission
duration was  longer in DM patients. MACE at 6 months were sig-
niﬁcantly higher in diabetic hypertensive patients comparison with
the other groups. At 6 months and 12 months, cardiac and all-cause
deaths developed more frequently in the diabetic hypertensive
group than other groups, but other end points were not signiﬁcantly
different between the four groups. During the 12-month follow-
up period, all-cause death-free survival and death/MI-free survival
were lowest in group 4 (Fig. 1A and B, log-rank p < 0.001, log-rank
p < 0.001, respectively). Also, the primary end point occurred in
93 patients (15.9%) in group 1, 104 patients (22.9%) in group 2,
72 patients (28.8) in group 3, and 133 patients (37.0%) in group
4 (Fig. 1D, log-rank p < 0.001). In contrast, revascularization-free
survival was not signiﬁcantly different between the four groups
(Fig. 1C, log-rank p = 0.306).
Independent predictors of MACE
The results of univariate and multivariate analysis using Cox
proportional hazard model adjusting for other potential clini-
cal predictors of mortality are shown in Table 4. After adjusting
for many covariates, old age, high Killip class, low LVEF, low
eGFR, multivessel disease, and implantation of bare metal stent
260 M.G. Lee et al. / Journal of Cardiology 60 (2012) 257–263
Table 2
Coronary angiographic and procedural characteristics.
Group 1 (n = 854) Group 2 (n = 663) Group 3 (n = 366) Group 4 (n = 555) p-value§
Location of culprit lesion, n (%)
Left main coronary artery 27 (3.2) 20 (3.0) 16 (4.5) 22 (4.0) 0.322
Left  anterior descending artery 430 (50.4) 308 (46.4) 175 (47.8) 224 (40.4) 0.001
Left  circumﬂex artery 126 (14.7) 122 (18.5) 53 (14.5) 115 (20.8) 0.02
Right  coronary artery 271 (31.7) 213 (32.1) 122 (33.2) 194 (34.9) 0.217
Multivessel disease, n (%) 342 (40.1) 339 (51.2) 191 (52.1) 335 (60.4) <0.001
ACC/AHA lesion type, n (%)
A/B1 84 (9.8) 52 (7.8) 29 (8.0) 46 (8.3) 0.354
B2 683 (80.0) 530 (80.0) 290 (79.2) 447 (80.6) 0.872
C  87 (10.1) 81 (12.2) 47 (12.8) 62 (11.1) 0.489
Pre-PCI TIMI ﬂow grade, n (%)
0  395 (46.2) 298 (45.0) 179 (49.0) 229 (41.2) 0.178
I  37 (4.3) 33 (5.0) 18 (5.0) 25 (4.5) 0.814
II  225 (26.3) 178 (26.8) 91 (24.9) 171 (30.8) 0.140
III 197 (23.1) 154 (23.2) 77 (21.1) 130 (23.4) 0.928
Post-PCI TIMI ﬂow grade, n (%)
0 13 (1.5) 11 (1.7) 10 (2.7) 10 (1.9) 0.398
I 0 (0)  3 (0.5) 0 (0) 1 (0.2) 0.726
II  8 (0.9) 9 (1.3) 8 (2.1) 6 (1.1) 0.543
III 833 (97.6) 640 (96.5) 348 (95.3) 538 (96.8) 0.271
Stent  implantation, n (%) 816 (95.6) 623 (94.9) 349 (95.4) 528 (95.1) 0.744
Stent  types, n (%)
Bare-metal stents 126 (15.5) 116 (18.7) 60 (16.3) 116 (21.9) 0.017
Drug-eluting stents
Paclitaxel-eluting stents 176 (21.6) 129 (20.7) 78 (22.3) 101 (19.2) 0.440
Sirolimus-eluting stents 64 (7.8) 42 (6.7) 17 (5.0) 28 (5.3) 0.056
Zotarolimus-eluting stents 188 (23.1) 138 (22.2) 91 (26.2) 113 (21.4) 0.810
Everolimus-eluting stents 137 (16.8) 101 (16.2) 66 (18.9) 110 (20.8) 0.066
Biolimus-eluting stents 54 (6.6) 51 (8.2) 7 (2.0) 27 (5.1) 0.045
EPC-capturing stents 70 (8.6) 45 (7.3) 32 (9.3) 34 (6.4) 0.334
Stent  diameter (mm)† 3.27 ± 0.43a 3.19 ± 0.39b 3.19 ± 0.39b 3.16 ± 0.39b <0.001*
Stent length (mm) 22.8 ± 6.6 23.3 ± 6.7 23.9 ± 6.7 23.2 ± 7.3 0.108*
Number of stents† 1.6 ± 0.9a 1.7 ± 0.9a 1.7 ± 0.9a 1.8 ± 0.9b 0.004*
GP IIb/IIIa inhibitors use, n (%) 238 (27.9) 158 (23.9) 92 (25.2) 130 (23.5) 0.112
Successful result of PCI, n (%) 830 (97.2) 634 (95.6) 347 (94.8) 534 (96.2) 0.116
Data are given as mean ± SD or n (%).
Group 1 = neither previous diagnosis of diabetes nor hypertension. Group 2 = previous diagnosis of hypertension and no diabetes. Group 3 = previous diagnosis of diabetes
and  no hypertension. Group 4 = known diabetes and hypertension.
ACC/AHA, American College of Cardiology/American Heart Association; PCI, percutaneous coronary intervention; TIMI, Thrombolysis In Myocardial Infarction; EPC, endothelial
progenitor cell; GP, glycoprotein.






















m* Statistical signiﬁcances were tested by analysis of variance among groups.
† The same letters indicate non-signiﬁcant difference between groups based on m
ere independent predictors of 12-month MACE. Also, DM or
ypertension, especially the combination of DM and hypertension,
igniﬁcantly increased the risk of MACE. In contrast, medication
ith beta blocker or statin signiﬁcantly decreased 12-month mor-
ality.
iscussion
The main ﬁnding of the present study is that acute MI  patients
ith a history of DM or hypertension or both had a higher mortality
uring a mid-term follow-up of 1 year as compared to patients
ithout such a history in the era of PCI. Also, the combination of
M and hypertension was a more important predictor for mortality
han DM or hypertension alone.
Hypertension is a powerful risk factor for cardiovascular
orbidity and mortality. Epidemiologic studies of treated and
ntreated hypertensive patients conﬁrmed that there was a grad-
ally increasing incidence of CAD, stroke, and cardiovascular
ortality as the blood pressure rises above 110/75 mmHg  [16]. In
articular, several studies have reported that antecedent hyperten-
ion after MI  is associated with adverse cardiovascular outcomes
uch as stroke, heart failure, and cardiovascular death [17–19].  DM
s a complex metabolic state requiring a persistent evaluation of
lood glucose in association with a wide range of additional abnor-
alities. Raised glucose levels in the circulation may  speed up thele comparison test.
process of atherosclerosis through putative mechanisms such as
oxidative stress and protein glycation of vessel walls [20,21]. Due to
these pathogenic aspects, DM increases the risk of CAD mortality 2-
to 5-fold compared with non-diabetic subjects of similar age, espe-
cially women, who lose the protective effect of their gender [22].
Also, DM is a leading cause of end-stage renal disease, blindness,
and non-traumatic amputations. Patients with DM prior to MI  were
at particularly high risk for further cardiovascular complications. It
is estimated that a high proportion of persons with hypertension
has insulin resistance or impaired glucose tolerance [4]. Besides,
clustering of hypertension, insulin resistance, overt type 2 DM,
dyslipidemia, and central obesity has been documented in several
populations [23]. Considerable experimental and clinical evidence
indicates that elevated blood pressure is critically important in the
pathogenesis of diabetic heart disease [1,23].
Both hypertension and DM are well-identiﬁed risk factors for
atherogenesis [24]. CAD is much more common in patients with
both DM and hypertension than in patients with DM or hyper-
tension alone, and the development of atherosclerosis was found
to be accelerated [25,26].  One study reported that concentric left
ventricular hypertrophy causes deterioration of systolic myocardial
deformation in patients with hypertension [27]. A previous study
showed early appearance of adverse myocardial functional and
geometric changes in diabetic patients and the contributory effects
of DM to myocardial impairment and left ventricular hypertrophy
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Table  3
Adverse Events at 1-year follow-up.
Group 1 (n = 854) Group 2 (n = 663) Group 3 (n = 366) Group 4 (n = 555) p-value§
In-hospital outcomes
Total death, n (%) 25 (2.9) 29 (4.4) 32 (8.8) 52 (9.3) <0.001
CCU  duration (days)† 2.4 ± 1.9a 2.8 ± 2.4b 3.5 ± 4.0c 3.5 ± 3.7c <0.001*
6-month outcomes, n (%)
Cardiac death 25 (4.1) 27 (5.7) 31 (11.8) 53 (14.0) <0.001
All-cause death 31 (5.1) 35 (7.4) 38 (14.5) 65 (17.2) <0.001
Myocardial infarction 5 (0.8) 6 (1.3) 2 (0.8) 4 (1.1) 0.835
Repeated PCI 37 (6.1) 31 (6.6) 19 (7.3) 30 (7.9) 0.233
TLR 22 (3.6) 16 (3.4) 14 (5.3) 18 (4.8) 0.225
CABG 1 (0.2) 2 (0.4) 1 (0.4) 1 (0.3) 0.750
MACE  77 (12.6) 82 (17.4) 63 (24.0) 112 (29.6) <0.001
12-month outcomes, n (%)
Cardiac death 28 (4.8) 33 (7.3) 32 (12.8) 59 (16.4) <0.001
All-cause death 32 (5.5) 37 (8.1) 39 (15.6) 67 (18.7) <0.001
Myocardial infarction 5 (0.9) 9 (2.0) 3 (1.2) 8 (2.2) 0.150
Repeated PCI 49 (8.4) 43 (9.5) 25 (10.0) 43 (12.0) 0.071
TLR  30 (5.1) 22 (4.8) 18 (7.2) 28 (7.8) 0.054
CABG 1(0.2) 2 (0.4) 1 (0.4) 1 (0.3) 0.743
MACE  93 (15.9) 104 (22.9) 72 (28.8) 133 (37.0) <0.001
Deﬁnite/probable ST 13 (2.1) 8 (1.7) 7 (2.7) 10 (2.7) 0.466
Data are given as mean ± SD or n (%).
Group 1 = neither previous diagnosis of diabetes nor hypertension. Group 2 = previous diagnosis of hypertension and no diabetes. Group 3 = previous diagnosis of diabetes
and  no hypertension. Group 4 = known diabetes and hypertension.
CCU, coronary care unit; PCI, percutaneous coronary intervention; TLR, target lesion revascularization; CABG, coronary artery bypass grafting; MACE, major adverse cardiac























I§ Statistical signiﬁcances for linear-by-linear association between categorical var
* Statistical signiﬁcances were tested by analysis of variance among groups.
† The same letters indicate non-signiﬁcant difference between groups based on m
ere produced by the presence of hypertension [28]. Patients with
ombined DM and hypertension tend to have impaired systolic
nd diastolic left ventricular function with more severe left ventri-
ular hypertrophy and congestive heart failure than counterparts
ith hypertension or DM alone [25,28]. As expected, LVEF was
igniﬁcantly lower in diabetic hypertensive patients. Also, many
revious studies demonstrated that hospital case-fatality rates for
iabetic patients with ACS were signiﬁcantly higher than non-
iabetic patients [29–31],  and that DM is one of the most important
isk factors for new cardiovascular events following an acute MI
32]. It can be easily expected that coexistence of hypertension and
M in the same patient is devastating to the cardiovascular sys-
em, especially after acute MI.  These poor prognostic outlooks for
iabetic hypertensive patients may  be explained by manyfactors
able 4
nivariate and multivariate analysis for independent predictors of 12-month MACE.
Unadjusted HR 95% CI 
Group 1
Group 2 1.484 1.122–1.963 
Group 3 1.799 1.319–2.453 
Group 4 2.458 1.882–3.211 
Male 0.651 0.532–0.797 
Old  age (≥65) 2.048 1.665–2.518 
STEMI 1.116 0.918–1.356 
Previous history of CVA 1.719 1.243–2.376 
Smoking 0.689 0.568–0.837 
High  Killip class ((III) 3.176 2.593–3.890 
Low  LVEF (<40%) 2.459 1.908–3.168 
Low  eGFR (<60 ml/min) 2.041 1.613–2.582 
Multivessel disease 1.413 1.146–1.744 
Implantation of BMS  1.824 1.416–2.349 
Low  post-PCI TIMI ﬂow ((II) 5.514 3.689–7.200 
Beta  blocker 0.339 0.276–0.417 
Statin  0.429 0.352–0.524 
roup 1 = neither previous diagnosis of diabetes nor hypertension. Group 2 = previous di
nd  no hypertension. Group 4 = known diabetes and hypertension.
ACE, major adverse cardiac events; HR, hazard ratio; CI, conﬁdence interval; STEMI, ST-
entricular ejection fraction; eGFR, estimated glomerular ﬁltration rate; BMS, bare-metal
nfarction. were tested using chi-square test for trend.
le comparison test.
such as increased platelet activity, decreased ﬁbrinolysis, small ves-
sel disease, diabetic cardiomyopathy, and autonomic neuropathy
leading to ventricular arrhythmia [33,34]. Also, the presence of
hyperglycemia in STEMI patients is associated with the impairment
of epicardial coronary ﬂow after primary stent implantation, and
this mechanism might be responsible for the increased infarct size
[35]. Our study demonstrated that in diabetic hypertensive patients
the in-hospital and 1-year outcomes were signiﬁcantly worse com-
pared to patients with hypertension or DM alone. This higher risk
of diabetic patients with hypertension remained after adjustments
were made for different clinical variables. Although a recent study
showed that hypertension does not seem to be associated with a
higher mortality rate after PCI when it is not combined with DM,
it included more stable patients such as stable CAD and unstable
p-value Adjusted HR 95% CI p-value
0.006 1.449 1.005–2.088 0.047
<0.001 1.597 1.129–2.259 0.008
<0.001 1.790 1.313–2.442 <0.001
<0.001 1.063 0.756–1.494 0.727
<0.001 1.420 1.062–1.898 0.018
0.270 0.997 0.771–1.290 0.984
0.001 1.164 0.740–1.829 0.511
<0.001 0.894 0.644–1.241 0.447
<0.001 1.367 1.039–1.798 0.026
<0.001 1.777 1.295–2.439 <0.001
<0.001 1.480 1.103–1.987 0.009
0.001 1.456 1.112–1.905 0.006
<0.001 1.386 1.037–1.851 0.027
<0.001 2.259 0.910–5.603 0.079
<0.001 0.494 0.354–0.691 <0.001
<0.001 0.689 0.521–0.911 0.009
agnosis of hypertension and no diabetes. Group 3 = previous diagnosis of diabetes
segment elevation myocardial infarction; CVA, cerebrovascular accident; LVEF, left
 stent; PCI, percutaneous coronary intervention; TIMI, Thrombolysis In Myocardial
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Fig. 1. Freedom from all-cause death (A), death and MI  (B), revascularization (C), and MACE (D) at 1 year in the 4 groups (Kaplan–Meier curves). DM (−), HTN (−) = neither
previous diagnosis of diabetes nor hypertension. DM (−), HTN (+) = previous diagnosis of hypertension and no diabetes. DM (+), HTN (−) = previous diagnosis of diabetes and

















io  hypertension. DM (+), HTN (+) = known diabetes and hypertension. The MACE is
I,  myocardial infarction; MACE, major adverse cardiac event.
ngina and estimated other endpoints such as stroke and hospi-
alization for heart failure compared with our study [36]. Another
revious study showed a lower mortality rate than the present
tudy, but this result may  be caused by inclusion of acute MI  as
ell as lower risk population such as unstable angina [11]. These
ifferences may  contribute to the discrepancy between their results
nd ours.
The prevalence of multi-vessel disease appears to be higher in
M and hypertensive patients. Along with diabetic cardiomyopa-
hy, endothelial dysfunction, prothrombogenic activity, and several
ther risk factors, this might partly explain the association between
M and hypertension on the one hand and the increased mortal-
ty on the other. This assumption was based on the result from a
ubset of patients and remains to be conﬁrmed after adjustment
or confounding factors. That is, our study showed that diabetic
ypertensive patients have a higher prevalence of multi-vessel
nvolvement than the control, non-diabetic, and normotensivemposite of death, recurrent myocardial infarction, and coronary revascularization.
diabetic populations following an acute MI  and multivessel dis-
ease is related to worse mid-term clinical outcome. This ﬁnding is
consistent with the results of a previous study [37].
Study limitations
The present study had several limitations. First, this study is
an observational and nonrandomized retrospective single-center
study, so, is subject to limitations inherent in this type of clinical
investigation. Although multivariate analysis was  used to adjust for
baseline characteristics, residual unmeasured confounding factors
might have remained. But our study dose reﬂect the “real world”
population in that it includes all consecutive patients hospitalized
with acute MI  in a self-contained health care system and thus pro-
vides important insights into the treatment and outcomes of such
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e could not determine the true incidence of DM,  especially among
ersons without a prior history of this condition. Third, information
n blood pressure and diabetes control over the follow-up period
s lacking in many patients, therefore we cannot assess directly its
mpact on prognosis. Finally, there might be some selection bias
elated to the fact that our center is a high-volume tertiary center
ith a sizeable proportion of patients referred from other hospitals.
onclusions
This study demonstrated that acute MI  patients with a history of
ypertension and DM have a higher risk of MACE during mid-term
ollow-up than non-hypertensive, non-diabetic patients in the era
f PCI. The combination of DM and hypertension appeared to be
ore strongly associated with mortality than DM or hypertension
lone.
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